Clinical bottom line
Emerging evidence highlights the significant role of microbiome alterations in urological health and disease, particularly in conditions such as benign prostatic hyperplasia (BPH) and chronic kidney disease (CKD). Gut and urinary tract microbiota dysbiosis may influence inflammatory pathways, metabolic profiles, and symptom severity in urological disorders. While mechanistic insights are expanding, clinical translation remains in early stages, warranting cautious interpretation. Integrating microbiome considerations into urological practice could open novel preventive and therapeutic avenues, but further research is needed to establish causality and effective interventions (Cai et al., 2025; Rysz et al., 2021).
What the evidence shows
Cai et al. (2025) review the impact of lifestyle and microbiome composition on male lower urinary tract symptoms (LUTS) due to BPH. They report associations between altered gut microbiota profiles and increased prostatic inflammation, suggesting that microbiome modulation may influence symptom burden and disease progression.
Rysz et al. (2021) discuss how CKD affects gut microbiota, leading to accumulation of uremic toxins that exacerbate systemic inflammation and renal dysfunction. These microbiome-derived metabolites may also impact urinary tract health and contribute to urological complications.
Hsu et al. (2022) demonstrate that maternal diet-induced gut microbiome changes can program offspring susceptibility to adult diseases, implying that early-life microbiome alterations might have long-term urological implications.
Although not urology-specific, Fan et al. (2023) illustrate how gut microbiota influence systemic inflammatory and immune responses, mechanisms potentially relevant to urological diseases characterized by chronic inflammation.
Caveats and uncertainty
Most studies are observational or preclinical, limiting causal inference between microbiome alterations and urological disease.
Microbiome composition varies widely among individuals and is influenced by diet, medications, and comorbidities, complicating standardization.
Interventional trials targeting the microbiome in urological conditions are scarce, and optimal strategies (e.g., probiotics, diet modification) remain undefined.
The interplay between gut and urinary tract microbiomes and their relative contributions to disease pathophysiology require further elucidation.
Potential confounders such as antibiotic use and lifestyle factors may bias associations.
How this may change practice
Clinicians should recognize the potential influence of microbiome health on urological conditions, particularly in patients with BPH and CKD.
Lifestyle interventions promoting gut microbiome diversity, such as dietary modification, may be considered adjunctively in managing LUTS.
Future integration of microbiome profiling could aid risk stratification and personalized therapy in urology.
Research participation and multidisciplinary collaboration are encouraged to advance microbiome-targeted therapeutics.
Awareness of microbiome impacts may inform antibiotic stewardship to preserve beneficial microbial communities.